Current limitations and future opportunities for epigenetic therapies

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Jones PA, Baylin SB. The epigenomics of cancer. Cell128,683–692 (2007).
  Medline CASGoogle Scholar
• 2  Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet.7(1),21–33 (2006).
  Medline CASGoogle Scholar
• 3  Jurkowska RZ, Jurkowski TP, Jeltsch A. Structure and function of mammalian DNA methyltransferases. ChemBioChem12(2),206–222 (2011).
  Medline CASGoogle Scholar
• 4  Jones PA, Liang GN. Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet.10(11),805–811 (2009).
  Medline CASGoogle Scholar
• 5  Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci.31(2),89–97 (2006).
  Medline CASGoogle Scholar
• 6  Watt F, Molloy Pl. Cytosine methylation prevents binding to DNA of a Hela-cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev.2(9),1136–1143 (1988).
  Medline CASGoogle Scholar
• 7  Boyes J, Bird A. DNA methylation inhibits transcription indirectly via a methyl-Cpg binding-protein. Cell64(6),1123–1134 (1991).
  Medline CASGoogle Scholar
• 8  Wade PA. Methyl CpG binding proteins: coupling chromatin architecture to gene regulation. Oncogene20(24),3166–3173 (2001).
  Medline CASGoogle Scholar
• 9  Strahl BD, Allis CD. The language of covalent histone modifications. Nature403(6765),41–45 (2000).
  Medline CASGoogle Scholar
• 10  Lall S. Primers on chromatin. Nat. Struct. Biol.14(11),1110–1115 (2007).
  CASGoogle Scholar
• 11  Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res.21(3),381–395 (2011).▪▪ Recent and comprehensive review on the effect of histone modifications on transcription.
  Medline CASGoogle Scholar
• 12  Suganuma T, Workman JL. Signals and combinatorial functions of histone modifications. Annu. Rev. Biochem.80,473–499 (2011).
  Medline CASGoogle Scholar
• 13  Kouzarides T. Chromatin modifications and their function. Cell128(4),693–705 (2007).
  Medline CASGoogle Scholar
• 14  Wiencke JK, Zheng S, Morrison Z, Yeh RF. Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells. Oncogene27(17),2412–2421 (2008).
  Medline CASGoogle Scholar
• 15  Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res.48(5),1159–1161 (1988).
  Medline CASGoogle Scholar
• 16  Lapeyre J-N, Becker FF. 5-methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result. Biochem. Biophys. Res. Commun.87(3),698–705 (1979).
  Medline CASGoogle Scholar
• 17  Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med.349(21),2042–2054 (2003).
  Medline CASGoogle Scholar
• 18  Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature395(6697),89–93 (1998).
  Medline CASGoogle Scholar
• 19  Taby R, Issa J-PJ. Cancer epigenetics. CA Cancer J. Clin.60(6),376–392 (2010).
  MedlineGoogle Scholar
• 20  Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science300(5618),455 (2003).
  Medline CASGoogle Scholar
• 21  Toyota M, Issa J-PJ. The role of DNA hypermethylation in human neoplasia. Electrophoresis21(2),329–333 (2000).
  Medline CASGoogle Scholar
• 22  Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene21(35),5427–5440 (2002).
  Medline CASGoogle Scholar
• 23  Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Gen.16(R1),R50–R59 (2007).
  Medline CASGoogle Scholar
• 24  Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res.21(3),502–517 (2011).
  Medline CASGoogle Scholar
• 25  Schuebel KE, Chen W, Cope L et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLos Genet.3(9),1709–1723 (2007).
  Medline CASGoogle Scholar
• 26  Zardo G, Tirikainen MI, Hong CB et al. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nat. Genet.32(3),453–458 (2002).
  Medline CASGoogle Scholar
• 27  Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell5(5),455–463 (2004).
  Medline CASGoogle Scholar
• 28  Ropero S, Fraga MF, Ballestar E et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet.38(5),566–569 (2006).
  Medline CASGoogle Scholar
• 29  Moore SDP, Herrick SR, Ince TA et al. Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF. Cancer Res.64(16),5570–5577 (2004).
  Medline CASGoogle Scholar
• 30  Bryan EJ, Jokubaitis VJ, Chamberlain NL et al. Mutation analysis of EP300 in colon, breast and ovarian carcinomas. Int. J. Cancer102(2),137–141 (2002).
  Medline CASGoogle Scholar
• 31  Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature463(7279),360–363 (2010).
  Medline CASGoogle Scholar
• 32  Hamamoto R, Furukawa Y, Morita M et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol.6(8),731–740 (2004).
  Medline CASGoogle Scholar
• 33  Portela A, Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol.28,1057–1068 (2010).
  Medline CASGoogle Scholar
• 34  Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet.37(4),391–400 (2005).
  Medline CASGoogle Scholar
• 35  Kondo Y, Shen L, Suzuki S et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol. Res.37(11),974–983 (2007).
  Medline CASGoogle Scholar
• 36  Vire E, Brenner C, Deplus R et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature439(7078),871–874 (2006).▪ Demonstration of interplay between H3K27 methylation by EZH2 and DNA methylation.
  Medline CASGoogle Scholar
• 37  Derks S, Bosch LJW, Niessen HEC et al. Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. Carcinogenesis30(6),1041–1048 (2009).
  Medline CASGoogle Scholar
• 38  Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet.21(1),103–107 (1999).
  Medline CASGoogle Scholar
• 39  Plumb JA, Steele N, Finn P, Brown R. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br. J. Cancer100(5),758–763 (2009).
  MedlineGoogle Scholar
• 40  Issa JP, Kantarjian HM. Targeting DNA methylation. Clin. Cancer Res.15,3938–3946 (2009).
  Medline CASGoogle Scholar
• 41  Weinstein IB, Joe A. Oncogene addiction. Cancer Res.68(9),3077–3080 (2008).
  Medline CASGoogle Scholar
• 42  Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat. Biotech.28(10),1069–1078 (2010).
  Medline CASGoogle Scholar
• 43  Plagemann PGW, Behrens M, Abraham D. Metabolism and cytotoxicity of 5-azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia-cells and their enhancement by pre-incubation with pyrazofurin. Cancer Res.38(8),2458–2466 (1978).
  Medline CASGoogle Scholar
• 44  Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer123(1),8–13 (2008).
  Medline CASGoogle Scholar
• 45  Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res.66(5),2794–2800 (2006).
  Medline CASGoogle Scholar
• 46  Chuang JC, Yoo CB, Kwan JM et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol. Cancer Ther.4(10),1515–1520 (2005).
  Medline CASGoogle Scholar
• 47  Siedlecki P, Boy RG, Musch T et al. Discovery of two novel, small-molecule inhibitors of DNA methylation. J. Med. Chem.49(2),678–683 (2005).
  Google Scholar
• 48  Suzuki T, Tanaka R, Hamada S, Nakagawa H, Miyata N. Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. Bioorg. Med. Chem. Lett.20(3),1124–1127 (2010).
  Medline CASGoogle Scholar
• 49  Piña IC, Gautschi JT, Wang G-Y-S et al. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem.68(10),3866–3873 (2003).
  Medline CASGoogle Scholar
• 50  Nebbioso A, Pereira R, Khanwalkar H et al. Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor, UVI5008. Mol. Cancer Ther.10(12),2394–2404 (2011).
  Medline CASGoogle Scholar
• 51  Lin J, Haffner MC, Zhang Y et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate71(4),333–343 (2011).
  Medline CASGoogle Scholar
• 52  García J, Franci G, Pereira R et al. Epigenetic profiling of the antitumor natural product psammaplin A and its analogues. Bioorg. Med. Chem.19(12),3637–3649 (2011).
  Medline CASGoogle Scholar
• 53  Baud MGJ, Leiser T, Haus P et al. Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. J. Med. Chem. doi: 10.1021/jm2016182 (2012) (Epub ahead of print).
  MedlineGoogle Scholar
• 54  Godert AM, Angelino N, Woloszynska-Read A et al. An improved synthesis of psammaplin A. Bioorg. Med. Chem. Lett.16(12),3330–3333 (2006).
  Medline CASGoogle Scholar
• 55  Beisler JA. Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. J. Med. Chem.21(2),204–208 (1978).
  Medline CASGoogle Scholar
• 56  Yoo CB, Jeong S, Egger G et al. Delivery of 5-aza-2´-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res.67(13),6400–6408 (2007).
  Medline CASGoogle Scholar
• 57  Chabot GG, Rivard GE, Momparler RL. Plasma and cerebrospinal-fluid pharmacokinetics of 5-aza-2´-deoxycytidine in rabbits and Dogs. Cancer Res.43(2),592–597 (1983).
  Medline CASGoogle Scholar
• 58  Mcgarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, Baylin SB. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res.66(7),3541–3549 (2006).
  Medline CASGoogle Scholar
• 59  Cheng JC. Preferential response of cancer cells to zebularine. Cancer Cell6,151–158 (2004).
  Medline CASGoogle Scholar
• 60  Chuang JC, Warner SL, Vollmer D et al. S110, a 5-aza-2´-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol. Cancer Ther.9(5),1443–1450 (2010).
  Medline CASGoogle Scholar
• 61  Flotho C, Claus R, Batz C et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia23(6),1019–1028 (2009).
  Medline CASGoogle Scholar
• 62  Zhu WG, Dai ZY, Ding HM et al. Increased expression of unmethylated CDKN2D by 5-aza-2´-deoxycytidine in human lung cancer cells. Oncogene20(53),7787–7796 (2001).
  Medline CASGoogle Scholar
• 63  De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl Acad. Sci. USA93(14),7149–7153 (1996).
  Medline CASGoogle Scholar
• 64  Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa J-PJ. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood111(4),2382–2384 (2008).▪▪ Global analysis of lysine acetylation’s cellular roles, demonstrating the broad implication of this modification in many cellular processes.
  Medline CASGoogle Scholar
• 65  Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett.277(1),8–21 (2009).
  Medline CASGoogle Scholar
• 66  North B, Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol.5(5),224 (2004).
  MedlineGoogle Scholar
• 67  Glozak Ma, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene363,15–23 (2005).
  Medline CASGoogle Scholar
• 68  Yao Y-L, Yang W-M. Beyond histone and deacetylase: an overview of cytoplasmic histone deacetylases and their nonhistone substrates. J. Biomed. Biotechnol. doi:10.1155/2011/146493 (2011) (Epub ahead of print).
  Google Scholar
• 69  Wilson BJ, Tremblay AM, Deblois G, Sylvain-Drolet G, Giguère V. An acetylation switch modulates the transcriptional activity of estrogen-related receptor α. Mol. Endocrinol.24(7),1349–1358 (2010).
  Medline CASGoogle Scholar
• 70  Mann M, Choudhary C, Kumar C et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science325(5942),834–840 (2009).
  MedlineGoogle Scholar
• 71  Xiong Y, Zhao SM, Xu W et al. Regulation of cellular metabolism by protein lysine acetylation. Science327(5968),1000–1004 (2010).
  MedlineGoogle Scholar
• 72  Zhao SM, Wang QJ, Zhang YK et al. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science327(5968),1004–1007 (2010).
  MedlineGoogle Scholar
• 73  Norvell A, Mcmahon SB. Rise of the rival. Science327(5968),964–965 (2010).
  Medline CASGoogle Scholar
• 74  Marks PA, Xu WS, Parmigiani Rb. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene26(37),5541–5552 (2007).
  MedlineGoogle Scholar
• 75  Ellis DJP, Lawman ZK, Bonham K. Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors. Biochem. Biophys. Res. Commun.367(3),656–662 (2008).
  Medline CASGoogle Scholar
• 76  Mottet D, Pirotte S, Lamour V et al. HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene28(2),243–256 (2008).
  MedlineGoogle Scholar
• 77  Sawa H, Murakami H, Kumagai M et al. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol.107(6),523–531 (2004).
  Medline CASGoogle Scholar
• 78  Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA97(18),10014–10019 (2000).
  Medline CASGoogle Scholar
• 79  Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin. Cancer Res.15(12),3947–3957 (2009).
  Medline CASGoogle Scholar
• 80  Chen Cs, Weng SC, Tseng PH, Lin HP. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem.280(46),38879–38887 (2005).
  Medline CASGoogle Scholar
• 81  Rhodes LV, Nitschke AM, Segar HC et al. The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol. Rep. (1),10–16 (2011).
  MedlineGoogle Scholar
• 82  Brest P, Lassalle S, Hofman V et al. MiR-129 5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer18(6),711–719 (2011).
  Medline CASGoogle Scholar
• 83  Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol.27,5459–5468 (2009).
  Medline CASGoogle Scholar
• 84  Baud MGJ, Leiser T, Meyer-Almes F-J, Fuchter MJ. New synthetic strategies towards psammaplin A, access to natural product analogues for biological evaluation. Org. Biomol. Chem.9(3),659–662 (2011).
  Medline CASGoogle Scholar
• 85  Peter A. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett.280(2),233–241 (2009).
  MedlineGoogle Scholar
• 86  Mann BS, Johnson JR Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist12(10),1247–1252 (2007).
  Medline CASGoogle Scholar
• 87  Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol.25(1),84–90 (2007).
  Medline CASGoogle Scholar
• 88  Whittaker SJ, Demierre M-F, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol.28(29),4485–4491 (2010).
  Medline CASGoogle Scholar
• 89  Piekarz Rl, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol.27(32),5410–5417 (2009).
  Medline CASGoogle Scholar
• 90  Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs69,1911–1934 (2009).
  Medline CASGoogle Scholar
• 91  Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett.280(2),211–221 (2009).
  Medline CASGoogle Scholar
• 92  Graham JS, Kaye SB, Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur. J. Cancer45(7),1129–1136 (2009).
  Medline CASGoogle Scholar
• 93  Siegel D, Hussein M, Belani C et al. Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol.27(2),31 (2009).
  Google Scholar
• 94  Galanis E, Jaeckle KA, Maurer MJ et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol.27(12),2052–2058 (2009).
  Medline CASGoogle Scholar
• 95  Steele NL, Plumb JA, Vidal L et al. A Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res.14(3),804–810 (2008).
  Medline CASGoogle Scholar
• 96  Modesitt SC, Sill M, Hoffman JS, Bender DP. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncol.109(2),182–186 (2008).
  Medline CASGoogle Scholar
• 97  Hussain M, Bradley D, Rathkopf D et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862) trial results and interleukin-6 analysis: a study by the department of defense prostate cancer clinical trial consortium and University of Chicago Phase II consortium. Cancer115(23),5541–5549 (2009).
  MedlineGoogle Scholar
• 98  Blumenschein GR, Kies MS, Papadimitrakopoulou VA et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest. New Drugs 26(1),81–87 (2008).
  Google Scholar
• 99  Somlo G, Luu TH, Morgan RJ et al. A Phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium Study. Clin. Cancer Res.14(21),7138–7142 (2008).
  MedlineGoogle Scholar
• 100  Thaler F, Minucci S. Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies? Expert Opin. Drug Disc.6(4),393–404 (2011).
  Medline CASGoogle Scholar
• 101  Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa J-PJ. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res.60(15),4044–4048 (2000).
  Medline CASGoogle Scholar
• 102  Chapman-Rothe N, Brown R. Approaches to target the genome and its epigenome in cancer. Future Med. Chem.1(8),1481–1495 (2009).
  CASGoogle Scholar
• 103  Yao X, Hu J-F, Daniels M et al. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J. Clin. Invest.111(2),265–273 (2003).
  Medline CASGoogle Scholar
• 104  Sasaki H, Moriyama S, Nakashima Y et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer46(2),171–178 (2004).
  MedlineGoogle Scholar
• 105  Gao D-J, Xu M, Zhang Y-Q et al. Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific SiRNA inhibits the growth of cancer cells. Pancreas39(7),949–1001 (2010).
  MedlineGoogle Scholar
• 106  Zhang Z, Yamashita H, Toyama T et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res. Tr.94(1),11–16 (2005).
  Medline CASGoogle Scholar
• 107  Krusche C, Wülfing P, Kersting C et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treat.90(1),15–23 (2005).
  Medline CASGoogle Scholar
• 108  Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin. Cancer Res.15(12),3918–3926 (2009).
  Medline CASGoogle Scholar
• 109  Qin T, Jelinek J, Si J, Shu J, Issa J-PJ. Mechanisms of resistance to 5-aza-2´-deoxycytidine in human cancer cell lines. Blood113(3),659–667 (2009).
  Medline CASGoogle Scholar
• 110  La Thangue NB, Khan O, Fotheringham S et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Natl Acad. Sci. USA107(14),6532–6537 (2010).
  MedlineGoogle Scholar
• 111  Spannhoff A, Sippl W, Jung M. Cancer treatment of the future: inhibitors of histone methyltransferases. Int. J. Biochem. Cell Biol.41(1),4–11 (2009).
  Medline CASGoogle Scholar
• 112  Spannhoff A, Hauser AT, Heinke R, Sippl W, Jung M. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem4(10),1568–1582 (2009).
  Medline CASGoogle Scholar
• 113  Lohse B, Kristensen JL, Kristensen LH et al. Inhibitors of histone demethylases. Bioorg. Med. Chem.19(12),3625–3636 (2011).
  Medline CASGoogle Scholar
• 114  Allis CD, Berger SL, Cote J et al. New nomenclature for chromatin-modifying enzymes. Cell131(4),633–636 (2007).
  Medline CASGoogle Scholar
• 115  Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov.8(9),724–732 (2009).▪▪ Comprehensive review on the promises of histone protein methyltransferase as targets.
  Medline CASGoogle Scholar
• 116  Hansen KH, Bracken AP, Pasini D et al. A model for transmission of the H3K27me3 epigenetic mark. Nat. Cell Biol.10(11),1291–1300 (2008).
  Medline CASGoogle Scholar
• 117  Qian C, Zhou M. SET domain protein lysine methyltransferases: structure, specificity and catalysis. Cell. Mol. Life Sci.63(23),2755–2763 (2006).
  Medline CASGoogle Scholar
• 118  Chuikov S, Kurash JK, Wilson JR et al. Regulation of p53 activity through lysine methylation. Nature432(7015),353–360 (2004).
  Medline CASGoogle Scholar
• 119  Huang J. G9a and Glp methylate lysine 373 in the tumor suppressor p53. J. Biol. Chem.285,9636–9641 (2010).
  Medline CASGoogle Scholar
• 120  Huang J, Perez-Burgos L, Placek Bj et al. Repression of p53 activity by Smyd2-mediated methylation. Nature444(7119),629–632 (2006).
  Medline CASGoogle Scholar
• 121  Shi X, Kachirskaia I, Yamaguchi H et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol. Cell27(4),636–646 (2007).
  Medline CASGoogle Scholar
• 122  Pradhan S, Chin HG, Estève P-O, Jacobsen SE: SET7/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics4(6),383–387 (2009).
  Medline CASGoogle Scholar
• 123  Yang X-D, Lamb A, Chen L-F. Methylation, a new epigenetic mark for protein stability. Epigenetics4(7),429–433 (2009).
  Medline CASGoogle Scholar
• 124  Rathert P, Dhayalan A, MAH, Jeltsch A. Specificity of protein lysine methyltransferases and methods for detection of lysine methylation of non-histone proteins. Mol. Biosyst.4(12),1186–1190 (2008).
  Medline CASGoogle Scholar
• 125  Bernstein BE, Mikkelsen TS, Xie X et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell125(2),315–326 (2006).
  Medline CASGoogle Scholar
• 126  Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell7(3),299–313 (2010).
  Medline CASGoogle Scholar
• 127  Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat. Rev. Genet.8(1),9–22 (2007).
  Medline CASGoogle Scholar
• 128  Baylin SB. Stem cells, cancer, and epigenetics. In: Stembook. The Stem Cell Research Community, Baltimore, MD, USA (2009).
  Google Scholar
• 129  Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. Fundam. Mol. Mech. Mutagen.647(1–2),21–29 (2008).▪▪ Review on EZH2 as a promising cancer target.
  Medline CASGoogle Scholar
• 130  Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med.313–319 (2011).
  MedlineGoogle Scholar
• 131  Suvà M-L, Riggi N, Janiszewska M et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res.69(24),9211–9218 (2009).
  Medline CASGoogle Scholar
• 132  Rizzo S, Hersey JM, Mellor P et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther.10(2),325–335 (2011).
  Medline CASGoogle Scholar
• 133  Albert M, Helin K. Histone methyltransferases in cancer. Sem. Cell Dev. Biol.21(2),209–220 (2010).
  Medline CASGoogle Scholar
• 134  Varier RA, Timmers HTM. Histone lysine methylation and demethylation pathways in cancer. BBA-Rev. Cancer1815(1),75–89 (2011).
  CASGoogle Scholar
• 135  Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin. Cancer Res.17(9),2613–2618 (2011).
  Medline CASGoogle Scholar
• 136  Tsang DPF, Cheng ASL. Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2. J. Gastroen. Hepatol.26(1),19–27 (2011).
  Medline CASGoogle Scholar
• 137  Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet.42(2),181-U124 (2010).
  Medline CASGoogle Scholar
• 138  Sneeringer CJ, Scott MP, Kuntz KW et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci.107(49),20980–20985 (2010).
  Medline CASGoogle Scholar
• 139  Yap DB, Chu J, Berg T et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood117(8),2451–2459 (2011).
  Medline CASGoogle Scholar
• 140  Van Haaften G, Dalgliesh GL, Davies H et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet.41(5),521–523 (2009).
  Medline CASGoogle Scholar
• 141  Takawa M, Masuda K, Kunizaki M et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci.102(7),1298–1305 (2011).
  Medline CASGoogle Scholar
• 142  Smith BC, Denu JM. Chemical mechanisms of histone lysine and arginine modifications. BBA Gene Reg. Mech.1789(1),45–57 (2009).
  CASGoogle Scholar
• 143  Cheng X, Zhang X. Structural dynamics of protein lysine methylation and demethylation. Mutat. Res. Fundam. Mol. Mech. Mutagen.618(1–2),102–115 (2007).
  Medline CASGoogle Scholar
• 144  Chin HG, Patnaik D, Esteve Po, Jacobsen SE, Pradhan S. Catalytic properties and kinetic mechanism of human recombinant lys-9 histone H3 methyltransferase SUV39H1: participation of the chromodomain in enzymatic catalysis. Biochemistry45(10),3272–3284 (2006).
  Medline CASGoogle Scholar
• 145  Patnaik D, Chin HG, Estève P-O, Benner J, Jacobsen Se, Pradhan S. Substrate specificity and kinetic mechanism of mammalian G9a histone H3 methyltransferase. J. Biol. Chem.279(51),53248–53258 (2004).
  Medline CASGoogle Scholar
• 146  Zhang X, Yang Z, Khan Si et al. Structural basis for the product specificity of histone lysine methyltransferases. Mol. Cell12(1),177–185 (2003).
  MedlineGoogle Scholar
• 147  Zhang X, Bruice TC. Enzymatic mechanism and product specificity of SET-domain protein lysine methyltransferases. Proc. Natl Acad. Sci. USA105(15),5728–5732 (2008).
  Medline CASGoogle Scholar
• 148  Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol.26(1),127–132 (2008).
  Medline CASGoogle Scholar
• 149  Cheng XD, Collins RE, Zhang X. Structural and sequence motifs of protein (histone) methylation enzymes. Annu. Rev. Biophys. Biomol. Struct.34,267–294 (2005).
  Medline CASGoogle Scholar
• 150  Mccammon MT, Parks LW. Inhibition of sterol transmethylation by S-adenosylhomocysteine analogs. J. Bacteriol.145(1),106–112 (1981).
  Medline CASGoogle Scholar
• 151  Daigle SR, Olhava Ej, Therkelsen CA et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell20(1),53–65 (2011).
  Medline CASGoogle Scholar
• 152  Tan J, Yang XJ, Zhuang L et al. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev.21(9),1050–1063 (2007).
  Medline CASGoogle Scholar
• 153  Glazer RI, Hartman KD, Knode MC et al. 3-deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia-cell line Hl-60. Biochem. Biophys. Res. Commun.135(2),688–694 (1986).
  Medline CASGoogle Scholar
• 154  Chiang PK, Cantoni GL. Perturbation of biochemical transmethylations by 3-deazaadenosine in vivo. Biochem. Pharmacol.28(12),1897–1902 (1979).
  Medline CASGoogle Scholar
• 155  Chiang PK. Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol. Ther.77(2),115–134 (1998).
  Medline CASGoogle Scholar
• 156  Miranda TB, Cortez CC, Yoo CB et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther.8,1579–1588 (2009).
  Medline CASGoogle Scholar
• 157  Zee BM, Levin RS, Xu B, Leroy G, Wingreen NS, Garcia BA. In vivo residue-specific histone methylation dynamics. J. Biol. Chem.285(5),3341–3350 (2010).
  Medline CASGoogle Scholar
• 158  Fiskus W, Pranpat M, Balasis M et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol. Cancer Ther.5(12),3096–3104 (2006).
  Medline CASGoogle Scholar
• 159  Fiskus W, Buckley K, Rao R et al. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol. Ther.8(10),939–950 (2009).
  Medline CASGoogle Scholar
• 160  Fiskus W, Wang YC, Jillella A et al. Combined epigenetic therapy with the novel histone methyl transferase EZH2 inhibitor 3-deazaneplanocin and -histone deacetylase inhibitor panobinostat exerts synergistic activity against human mantle cell lymphoma cells. Blood112(11),1239–1239 (2008).
  Google Scholar
• 161  Jiang X, Tan J, Li J et al. DACT3 Is an Epigenetic regulator of Wnt/≤-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell13(6),529–541 (2008).
  Medline CASGoogle Scholar
• 162  Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3–9. Nat. Chem. Biol.1(3),143–145 (2005).
  Medline CASGoogle Scholar
• 163  Hauser D, Weber HP, Sigg HP. Isolation and configuration of Chaetocin. Helv. Chim. Acta53(5),1061–1073 (1970).
  Medline CASGoogle Scholar
• 164  Gardiner DM, Waring P, Howlett BJ. The epipolythiodioxopiperazine (ETP) class of fungal toxins: distribution, mode of action, functions and biosynthesis. Microbiology151,1021–1032 (2005).
  Medline CASGoogle Scholar
• 165  Isham CR, Tibodeau JD, Jin W, Xu RF, Timm MM, Bible KC. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood109(6),2579–2588 (2007).
  Medline CASGoogle Scholar
• 166  Cook KM, Hilton ST, Mecinovic J, Motherwell WB, Figg WD, Schofield CJ. epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1α (hif-1α) and p300 by a zinc ejection mechanism. J. Biol. Chem.284(39),26831–26838 (2009).
  Medline CASGoogle Scholar
• 167  Saito T, Suzuki Y, Koyama K, Natori S, Iitaka Y, Kinoshita T. chetracin-A and chaetocin-B and chaetocin-C, 3 new epipolythiodioxopiperazines from Chaetomium Spp. Chem. Pharm. Bull.36(6),1942–1956 (1988).
  CASGoogle Scholar
• 168  Iwasa E, Hamashima Y, Fujishiro S et al. Total synthesis of (+)-chaetocin and its analogues: their histone methyltransferase G9a inhibitory activity. J. Am. Chem. Soc.132,4078–4079 (2010).
  Medline CASGoogle Scholar
• 169  Cherblanc F, Lo Y-P, De Gussem E et al. On the determination of the stereochemistry of semisynthetic natural product analogues using chiroptical spectroscopy: desulfurization of epidithiodioxopiperazine fungal metabolites. Chem. Eur. J.17(42),11868–11875 (2011).
  Medline CASGoogle Scholar
• 170  Kubicek S, O’Sullivan RJ, August EM et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell25,473–481 (2007).▪▪ Discovery of the original BIX-01294 G9a histone methyltransferase inhibitors.
  Medline CASGoogle Scholar
• 171  Chang Y, Zhang X, Horton Jr et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat. Struct. Mol. Biol.16(3),312–317 (2009).
  Medline CASGoogle Scholar
• 172  Liu F, Chen X, Allali-Hassani A et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J. Med. Chem.52(24),7950–7953 (2009).
  Medline CASGoogle Scholar
• 173  Liu F, Chen X, Allali-Hassani A et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J. Med. Chem.53(15),5844–5857 (2010).
  Medline CASGoogle Scholar
• 174  Liu F, Barsyte-Lovejoy D, Allali-Hassani A et al. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. J. Med. Chem.54(17),6139–6150 (2011).
  Medline CASGoogle Scholar
• 175  Vedadi M, Barsyte-Lovejoy D, Liu F et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol.7(8),566–574 (2011).
  Medline CASGoogle Scholar
• 176  Chang YQ, Ganesh T, Horton JR et al. Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J. Mol. Biol.400(1),1–7 (2010).
  Medline CASGoogle Scholar
• 177  Osborne T, Weller Roska RL, Rajski SR, Thompson PR. In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1. J. Am. Chem. Soc.130(14),4574–4575 (2008).
  Medline CASGoogle Scholar
• 178  Dowden J, Hong W, Parry RV, Pike RA, Ward SG. Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases. Bioorg. Med. Chem. Lett.20(7),2103–2105 (2010).
  Medline CASGoogle Scholar
• 179  Mori S, Iwase K, Iwanami N, Tanaka Y, Kagechika H, Hirano T. Development of novel bisubstrate-type inhibitors of histone methyltransferase SET7/9. Bioorg. Med. Chem.18(23),8158–8166 (2010).
  Medline CASGoogle Scholar
• 180  Howitz KT, Bitterman KJ, Cohen HY et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature425(6954),191–196 (2003).
  Medline CASGoogle Scholar
• 181  Choi SH, Kim YW, Kim SG. AMPK-mediated GSK3[β] inhibition by isoliquiritigenin contributes to protecting mitochondria against iron-catalyzed oxidative stress. Biochem. Pharmacol.79(9),1352–1362 (2010).
  Medline CASGoogle Scholar
• 201  The Regents of The University of Michigan: US2009/0012031 (2009).
  Google Scholar
• 202  GlaxoSmithKline LLC:US2011/035336 (2011).
  Google Scholar
• 301  Cancer Sleuths Uncovering DNA Mysteries for Novartis, Glaxo www.bloomberg.com/news/2011-05-12/cancer-sleuths-uncovering-dna-mysteries-for-novartis-glaxo.html
  Google Scholar
• 302  World Epigenetics Summit 2011 www.epigenie.com/Highlighted-Conferences/World-Epigenetics-Summit-2011-Conference-Coverage.html
  Google Scholar
• 303  EZH2 www.epizyme.com/programs/ezh2.asp
  Google Scholar